Table 2.

Characteristics of reported cases with TAFRO syndrome*

*We defined day 0 as initial therapy.

†The items were defined as follows: PLT improved: platelet count started to increase, PLT >100,000/µL: platelet count exceeds 100,000/µL, CRP improved: CRP started to decrease, CRP <1.0 mg/dL: CRP below1.0 mg/dL, Anasarca disappeared: pleural effusion and ascites had disappeared.

‡The patient was diagnosed with TAFRO syndrome after antibiotic therapy for cholangitis and infective endocarditis.

§0 day indicates CRP improved soon after initial therapy.

PLT: platelet, CRP:C-reactive protein, M: male, F: female, NA: not available, mPSL: methylprednisolone, DEX: dexamethasone, PSL: prednisolone, IVIG: intravenous immunoglobulin, TCZ: tocilizumab, GC: Glucocorticoid, Cy A: cyclosporine A, RTX: rituximab, PE: plasma exchange, ETP: etoposide, CHOP: cyclophosphamide, adriamycin, vincristine and prednisolone, CHOEP: cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone, IVCY: intermittent pulse intravenous cyclophosphamide therapy, R-CVP: rituximab, cyclophosphamide, vincristine and prednisolone, CEPP: cyclophosphamide, etoposide, procarbazine, and prednisolone, CMV: Cytomegalovirus, PCP: Pneumocystis pneumonia, AHRU: acute hemorrhagic rectal ulcer, CNS: coagulase negative staphylococci, GI: Gastrointestinal, T: treatment, Ref: reference.